|Awarded On||February 18, 2015|
|Title||Exploring molecular and immune mechanisms of response and resistance to combined BRAF/MEK inhibition in patients with high-risk resectable metastatic melanoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jennifer Wargo|
Melanoma is a major world health problem with an incidence that is rising rapidly. Tremendous progress has been made in the treatment of melanoma, including the discovery of the BRAF gene. Mutations in the BRAF gene occur in over half of melanomas, and result in a “short circuit” in melanoma cells, causing them to grow and spread. Treatment with BRAF inhibitors represents one of the most significant advances in decades, with tumors shrinking in up to 80% of patients. However tumors often grow back within 6 months. Our group has helped identify why tumors re-grow on therapy, and treatment strategies are now available to combat this. One way to do this is to give a BRAF inhibitor with a drug c...